Abstract
Nebulized Antithrombin (AT) decreased pulmonary coagulation and inflammation in a model of Acute Lung Injury (ALI) at 48h without altering systemic coagulation and no bleeding.
To evaluate the potential therapeutic effects of nebulized AT or Argatroban in an ALI model at 72h.
ALI was induced in rats by intratracheal HCl (0.1M) and Lipopolysaccharide (LPS 30μg/g body weight). Two or 3 doses of AT (500IU/Kg body weight) or 3 doses of Argatroban (1mg/Kg) were nebulized (AeronebPro nebulizer system, Aerogen Limited). Control animals received saline. Animals were sacrificed at 72h. Procoagulant, fibrinolytic, proinflammatory and chemoattractant molecules were evaluated. Statistics: One-Way-ANOVA and Newman Keuls post-hoc test was used. When data failed the normality test in the one-way ANOVA, Kruskal-Wallis was used (p≤0.05).
Anticoagulant treatment reduced mRNA proinflammatory (IL1β, TNFα) and chemoattractant molecules (Gro-kcα, MCP1) in lung tissue at 72h. Prolonged anticoagulant treatments also decreased antifibrinolytic PAI-1 and lung injury in the histopathologic scores. Nevertheless, myeloperoxidase levels were not decreased after anticoagulant treatment.
Nebulized anticoagulants reduce inflammation, neutrophils and monocytes recruitment in an ALI model at 72h, but only prolonged AT/Argatroban promote the fibrinolytic activation and reduce lung injury in the histologies.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2057.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
